Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | RESONATE: five-year follow-up of ibrutinib for CLL

Alessandra Tedeschi • 15 Jun 2019
EHA 2019
Chronic Lymphocytic Leukemia Ibrutinib Ofatumumab
RESONATE

The RESONATE phase III trial (NCT01578707) investigated whether treatment with ibrutinib as a monotherapy results in a clinically significant improvement in progression-free survival (PFS) as compared to treatment with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL). Alessandra Tedeschi, MD, of the Niguarda Cancer Center, Milan, Italy, discusses the results of a five-year follow-up of this study at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Alessandra Tedeschi

1:20
RESONATE-2: Ibrutinib for CLL 5-year follow-up
Alessandra Tedeschi • 21 Sep 2019
1:25
iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
Alessandra Tedeschi • 22 Sep 2019
17:22
Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi et al. • 21 Sep 2019
2:44
Waldenström’s Macroglobulinemia: frontline treatment
Alessandra Tedeschi • 15 Jun 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals